Compounds > bal101553
Page last updated: 2024-11-13

bal101553

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lisavanbulin: a prodrug of BAL27862 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID45259014
CHEMBL ID4297595
SCHEMBL ID1160313
MeSH IDM000608140

Synonyms (28)

Synonym
SCHEMBL1160313
hexanamide, 2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)-, (2s)-
microtubule-targeted agent bal101553
(2s)-2,6-diamino-n-{4-[2-(2-{4-[(2-cyanoethyl)amino]-1,2,5-oxadiazol-3-yl}-1h-benzimidazol-1-yl)acetyl]phenyl}hexanamide
lisavanbulin [who-dd]
lisavanbulin [usan:inn]
(2s)-2,6-diamino-n-(4-(2-(2-(4-((2-cyanoethyl)amino)-1,2,5-oxadiazol-3-yl)-1h-benzimidazol-1-yl)acetyl)phenyl)hexanamide
lisavanbulin [usan]
5PT0QP06X5 ,
bal-101553
lisavanbulin
1263384-43-5
lisavanbulin [inn]
bal101553
unii-5pt0qp06x5
who 10401
DB15224
D11494
lisavanbulin (usan/inn)
nsc764608
nsc-764608
Q27262705
CHEMBL4297595
bal 101553
EX-A4306
GLXC-25728
nsc-789724
nsc789724

Research Excerpts

Overview

BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells. It is currently in phase I/II clinical development.

ExcerptReferenceRelevance
"BAL101553 is a promising alternative in taxane- and epothilone-refractory tumors as part of a combined treatment modality with ionizing radiation. "( The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Bachmann, F; Broggini-Tenzer, A; Guckenberger, M; Lane, HA; Messikommer, A; Nytko, KJ; Pruschy, M; Sharma, A; Vuong, V, 2017)		2.17
"BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network. "( Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Kurmasheva, RT; Lock, RB; Maris, JM; Reynolds, CP; Smith, MA; Wu, J, 2015)		2.15
"BAL101553 is a prodrug of BAL27862, a novel microtubule-destabilizing agent inhibiting tumor cell proliferation through activation of the spindle assembly checkpoint, which is currently in phase I/II clinical development."( The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
Bachmann, F; Bergès, R; Braguer, D; Estève, MA; Figarella-Branger, D; Honoré, S; Lane, HA; Tchoghandjian, A, 2016)		1.41

Compound-Compound Interactions

BAL101553 or its active moiety BAL27862 were probed in combination with radiotherapy in P-glycoprotein-overexpressing, human colon adenocarcinoma cells (SW480) and tubulin-mutated human NSCLC cells.

ExcerptReferenceRelevance
" Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models."( The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Bachmann, F; Broggini-Tenzer, A; Guckenberger, M; Lane, HA; Messikommer, A; Nytko, KJ; Pruschy, M; Sharma, A; Vuong, V, 2017)		0.96
"Multiple regimens of BAL101553, or its active moiety BAL27862 for in vitro experiments, were probed in combination with radiotherapy in P-glycoprotein-overexpressing, human colon adenocarcinoma cells (SW480) and in tubulin-mutated human NSCLC cells (A549EpoB40) and tumors thereof."( The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Bachmann, F; Broggini-Tenzer, A; Guckenberger, M; Lane, HA; Messikommer, A; Nytko, KJ; Pruschy, M; Sharma, A; Vuong, V, 2017)		1.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (71.43)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.96 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
temozolomide
[no description available]		2.3110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		2.110alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
oxadiazoles
Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.		4.7861
ConditionIndicatedRelationship StrengthStudiesTrials
Astrocytoma, Grade IV
[description not available]		05.0942
Cancer of Ovary
[description not available]		03.9911
Local Neoplasm Recurrence
[description not available]		03.9911
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		112.0942
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		03.9911
Benign Neoplasms, Brain
[description not available]		04.0221
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		04.0221
Experimental Neoplasms
[description not available]		02.1510
Disease Exacerbation
[description not available]		03.5611
Cells, Neoplasm Circulating
[description not available]		03.5611